NCT03734770View on ClinicalTrials.gov

Patient's Preferences About Subcutaneous or Vaginal Progesterone Administration for Luteal Phase Support

NACompletedINTERVENTIONAL

Enrollment

149

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

March 1, 2019

Study Completion Date

July 1, 2019

Conditions

ProgesteroneLuteal Phase SupportIn Vitro Fertilization

Interventions

DRUG

Subcutaneous Progesterone

Subcutaneous progesterone (Pleyris, IBSA Farmaceutici, Italia) 25 mg one time per day (every day at the same time, according to patient's availability and preference).

DRUG

Vaginal progesterone

Micronized vaginal progesterone (Progeffik, EFFIK Spa, Italia) 200 mg three times per day (every 8 hours).

Trial Locations (1)

37125

AOUI Verona - University of Verona - Department of Obstetrics and Gynecology, Verona

All Listed Sponsors

lead

Universita di Verona

OTHER

NCT03734770 - Patient's Preferences About Subcutaneous or Vaginal Progesterone Administration for Luteal Phase Support | Biotech Hunter | Biotech Hunter